Otsuka Holdings (TYO:4578) said its unit, Taiho Pharmaceutical, will acquire Swiss biotech firm Araris Biotech for up to $1.14 billion to strengthen its antibody-drug conjugate (ADC) pipeline, according to a Monday filing on the Tokyo Stock Exchange.
Taiho will pay $400 million upfront and potential additional milestone payments of up to $740 million. The deal is expected to close in the first half of 2025.
Price (JPY): $7712.00, Change: $+94, Percent Change: +1.23%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.